RP1
1 clinical trial
1 product
4 abstracts
2 indications
Indication
Squamous Cell CarcinomaIndication
RP1Abstract
A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.Org: UPMC Hillman Cancer Center,
Abstract
Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.Org: Université Paris Cité, AP-HP Dermato-Oncology and CIC, Cancer Institute APHP, Aix-Marseille University, CEPCM, and CHU de La Timone APHM, Vall d'Hebron Institute of Oncology (VHIO) and Vall d'Hebron Hospital Medical Oncology Department, Leeds Institute of Medical Research at St. James’s, University of Leeds, Jonsson Comprehensive Cancer Center, University of California Los Angeles,
Clinical trial
A Phase 1B Study of Intralesional Injection of RP1 in Patients With Resectable Cutaneous SCCStatus: Recruiting, Estimated PCD: 2025-12-01
Abstract
Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study.Org: Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, The Clatterbridge Cancer Centre and University of Liverpool, Liverpool, United Kingdom, Intermountain Medical Center, Murray, UT, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA,
Product
RP1 + Nivolumab